Ambulero
Robert L. Buchanan is the Chief Executive Officer at Ambulero. Robert is a serial entrepreneur and investor; Entrepreneur-in-Residence, University of Miami, co-founder Idogen AS (IDOGEN: Spotlight); early investor RhoVAC AS (RHOVAC: Spotlight); GC Avexxin AS, Ph.D. UCLA, Biology Fellow CalTech, former Associate GC Biogen Inc, Ventac Partners LLC, Boston.
This person is not in any offices
Ambulero
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. A platform company that can deliver the adhesion molecule E-selectin using different cell and synthetic vector technologies.